Scandium radioisotopes are increasingly considered viable radiolabels for targeted molecular imaging (Sc-43, Sc-44) and therapy (Sc-47). Significant technological advances have increased the quantity and quality of available radioscandium in the past decade, motivated in part by the chemical similarity of scandium to therapeutic radionuclides like Lu-177. The production and radiochemical isolation techniques applied to scandium radioisotopes are reviewed, focusing on charged particle and electron linac initiated reactions and using calcium and titanium starting materials.
Next-generation high-intensity large acceptance fragment separators require a careful design due to the large high order aberrations induced by the large aperture superconducting magnets needed to collect rare isotopes obtained from a high energy primary heavy-ion beam hitting a target. In this paper we propose a fragment separator layout based on various symmetries that satisfies the baseline requirements. Analytical calculations based on symmetry theories simplify the design to numerical optimization of a basic cell with only a few magnetic elements. The insight provided by these calculations resulted in the specification of a simple layout with large acceptance, transmission, and resolution. The design method may be easily adapted to project-specific needs. The important effects of energy degraders necessary for full fragment separator design will be addressed in a future publication.
In recent years the use of beta-emitting radiopharmaceuticals for cancer therapy has expanded rapidly following development of therapeutics for neuroendocrine tumors, prostate cancer, and other oncologic malignancies. One emerging beta-emitting radioisotope of interest for therapy is 67Cu (t1/2: 2.6 d) due to its chemical equivalency with the widely-established positron-emitting isotope 64Cu (t1/2: 12.7 h). In this work we evaluate both the imaging and dosimetric characteristics of 67Cu, as well as producing the first report of SPECT/CT imaging using 67Cu. To this end, 67Cu was produced by photon-induced reactions on isotopically-enriched 68Zn at the Low-Energy Accelerator Facility (LEAF) of Argonne National Laboratory, followed by bulk separation of metallic 68Zn by sublimation and radiochemical purification by column chromatography. Gamma spectrometry was performed by efficiency-calibrated high-purity germanium (HPGe) analysis to verify absolute activity calibration and establish radionuclidic purity. Absolute activity measurements corroborated manufacturer-recommended dose-calibrator settings and no radionuclidic impurities were observed. Using the Clinical Trials Network anthropomorphic chest phantom, SPECT/CT images were acquired. Medium energy (ME) SPECT collimation was found to provide the best image quality from the primary 185 keV gamma emission of 67Cu. Reconstructed images of 67Cu were similar in quality to images acquired using 177Lu. Recovery coefficients were calculated and compared against quantitative images of 99mTc, 177Lu, and 64Cu within the same anthropomorphic chest phantom. Production and clinical imaging of 67Cu appears feasible, and future studies investigating the therapeutic efficacy of 67Cu-based radiopharmaceuticals are warranted.
A seconury beam of radioactive I7F was produced at the ATLAS accelerator and delivered to an experimental target station with an intensity of as much as 5-
Production of 99 Mo by the 100 Mo (γ, n) 99 Mo reaction through the bremsstrahlung process using an electron accelerator is one of the feasible options currently pursued by several countries. Here we report experimental results on identification of side-reaction products after the irradiation of natural and enriched 100 Mo targets. Side-reaction products identified include various Mo, Nb and Zr isotopes. Comparison of experimentally determined reaction production rates with those determined based on theoretical cross-sections will be presented. Moreover, activation products formed due to presence of impurities introduced during the manufacturing of the Mo targets will also be discussed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.